Related Experiment Video

Updated: Dec 20, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K

Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes

Nahla Fadl1, Tamer Z Salem1,2

  • 1Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, Egypt.

Reviews in Medical Virology
|June 2, 2020
PubMed

Insights

Hepatitis C virus (HCV) genotype 4 treatment responses vary due to genetic factors. This review focuses on genotype 4 variability and direct-acting antiviral agents, highlighting research gaps.

Area of Science:

  • Hepatology
  • Virology
  • Genetics

Background:

  • Hepatitis C virus (HCV) treatment responses exhibit significant patient variability.
  • Recent trials show non-responsiveness and relapse linked to host and viral genetic factors.
  • Existing clinical trials often underrepresent genotype 4, the most prevalent HCV type in Egypt and the Middle East.

Purpose of the Study:

  • To review genetic variabilities within HCV genes, particularly genotype 4, associated with treatment response.
  • To emphasize the role of direct-acting antiviral agents in managing HCV genotype 4.
  • To analyze global studies and clinical trials for their inclusion of genotype 4 patients.

Main Methods:

  • Comprehensive literature review of studies on HCV genetic variability and treatment response.
  • Focus on direct-acting antiviral agents and their efficacy across different HCV genotypes.
  • Analysis of clinical trial data regarding genotype 4 patient representation and outcomes.

Main Results:

  • Genotype 4 variability significantly impacts treatment outcomes in Hepatitis C virus patients.
  • Limited data exists on genotype 4-specific responses to direct-acting antiviral agents.
  • Global clinical trials have historically underrepresented genotype 4, hindering comprehensive analysis.

Conclusions:

  • Further research is crucial to understand genotype 4-specific genetic factors influencing treatment response.
  • Direct-acting antiviral agents require further investigation for optimal use in genotype 4 infections.
  • Addressing data gaps in genotype 4 research is essential for improving global HCV treatment strategies.
Keywords:
HCVdirect acting antiviralsgenetic variabilitygenotype 4resistance-associated substitutionsviral response

More Related Videos

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

1.8K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.0K

Related Concept Videos

Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.4K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.7K